Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. (Q42211518)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 June 2014

Language	Label	Description	Also known as
English	Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.	scientific article published on 19 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

K Kosaka

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

M Imamura

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

H Abe

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

N Hiraga

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

S Yoshimi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

E Murakami

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

T Kawaoka

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

M Tsuge

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

H Aikata

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

H Ochi

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

H Matsui

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

A Kanai

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

T Inaba

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

K Chayama

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

19 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

158-165

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Use of illumina deep sequencing technology to differentiate hepatitis C virus variants

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Fast and accurate short read alignment with Burrows-Wheeler transform

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12271

21 January 2018

Identifiers

10.1111/JVH.12271

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24943406%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42211518&oldid=1760237208"